250 related articles for article (PubMed ID: 36088616)
1. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
[TBL] [Abstract][Full Text] [Related]
2. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
3. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
[TBL] [Abstract][Full Text] [Related]
4. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
5. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Buonerba C; Ferro M; Dolce P; Crocetto F; Verde A; Lucarelli G; Scafuri L; Facchini S; Vaia A; Marinelli A; Terracciano D; Montella L; Longo N; Imbimbo C; Mirone V; Di Lorenzo G; De Placido S; Sonpavde G
Crit Rev Oncol Hematol; 2020 Jul; 151():102992. PubMed ID: 32474391
[TBL] [Abstract][Full Text] [Related]
6. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
[TBL] [Abstract][Full Text] [Related]
7. A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS).
Karim S; Lowther J; Gyulay G; O'Sullivan D; Wallis CJD; Yip SM; Brenner DR; Boyne DJ; Cheung WY
Curr Oncol; 2023 Sep; 30(9):8149-8158. PubMed ID: 37754506
[TBL] [Abstract][Full Text] [Related]
8. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.
Swami U; Isaacsson Velho P; Nussenzveig R; Chipman J; Sacristan Santos V; Erickson S; Dharmaraj D; Alva AS; Vaishampayan UN; Esther J; Hahn AW; Maughan BL; Antonarakis ES; Agarwal N
Eur Urol; 2020 Nov; 78(5):652-656. PubMed ID: 32624276
[TBL] [Abstract][Full Text] [Related]
9. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
Ferro M; Lucarelli G; Crocetto F; Dolce P; Verde A; La Civita E; Zappavigna S; de Cobelli O; Di Lorenzo G; Facchini BA; Scafuri L; Onofrio L; Porreca A; Busetto GM; Sonpavde G; Caraglia M; Klain M; Terracciano D; De Placido S; Buonerba C
Crit Rev Oncol Hematol; 2021 Jan; 157():103198. PubMed ID: 33316417
[TBL] [Abstract][Full Text] [Related]
10. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
Loriot Y; Eymard JC; Patrikidou A; Ileana E; Massard C; Albiges L; Di Palma M; Escudier B; Fizazi K
Eur J Cancer; 2015 Sep; 51(14):1946-52. PubMed ID: 26208462
[TBL] [Abstract][Full Text] [Related]
11. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients.
Pathak S; Thekkekara R; Yadav U; Ahmed AT; Yim B; Lad TE; Mullane M; Batra KK; Aronow WS; Psutka SP
Am J Ther; 2020 May; 28(4):e380-e387. PubMed ID: 32384317
[TBL] [Abstract][Full Text] [Related]
13. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
[TBL] [Abstract][Full Text] [Related]
14. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
Grisay G; Lavaud P; Fizazi K
Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
[TBL] [Abstract][Full Text] [Related]
15. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
17. Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer.
Wallis CJD; Malone S; Cagiannos I; Morgan SC; Hamilton RJ; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Niazi T; Noonan KL; Saad F; Hotte SJ; Hew H; Chan KFY; Wyllie LP; Shayegan B
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926988
[TBL] [Abstract][Full Text] [Related]
18. Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?
Nakagawa R; Iwamoto H; Naito R; Kadomoto S; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
Anticancer Res; 2023 Mar; 43(3):1351-1359. PubMed ID: 36854500
[TBL] [Abstract][Full Text] [Related]
19. Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Hattori K; Naito Y; Tochigi K; Sano T; Kawanishi H; Ishikawa T; Yuba T; Hattori R; Gotoh M; Tsuzuki T
BJU Int; 2020 May; 125(5):702-708. PubMed ID: 31833179
[TBL] [Abstract][Full Text] [Related]
20. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
